Corrigendum to 'IMscin001 Part 2: a randomised phase III, open-label, multicentre study examining the pharmacokinetics, efficacy, immunogenicity, and safety of atezolizumab subcutaneous versus intravenous administration in previously treated locally advanced or metastatic non-small-cell lung cancer and pharmacokinetics comparison with other approved indications': [Annals of Oncology 34 (2023) p693-702].
Ann Oncol
; 35(5): 482, 2024 May.
Article
en En
| MEDLINE
| ID: mdl-38195363
Texto completo:
1
Colección:
01-internacional
Banco de datos:
MEDLINE
Tipo de estudio:
Clinical_trials
Idioma:
En
Revista:
Ann Oncol
/
Ann. oncol
/
Annals of oncology
Asunto de la revista:
NEOPLASIAS
Año:
2024
Tipo del documento:
Article